Prevail Therapeutics $65.00 million Financing. ASA ABELIOVICH Published Mar 14 Filing

March 14, 2018 - By Maria Brooks

Prevail Therapeutics Financing

Prevail Therapeutics Inc., Corporation just released form D announcing $65.00 million equity financing. This is a new filing. Prevail Therapeutics was able to fundraise $57.00 million. That is 87.69 % of the financing round. The total private offering amount was $65.00 million. The offering form was filed on 2018-03-14. The reason for the financing was: unspecified. The fundraising still has about $8.00 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Prevail Therapeutics is based in New York. The firm’s business is Other Health Care. The form was filed by ASA ABELIOVICH PRESIDENT. The company was incorporated in 2017. The filler’s address is: 430 East 29Th Street, Suite 940, New York, Ny, New York, 10016. Asa Abeliovich is the related person in the form and it has address: C/O Prevail Therapeutics Inc., 430 East 29Th Street, Suite 940, New York, Ny, New York, 10016. Link to Prevail Therapeutics Filing: 000171479818000002.

Analysis of Prevail Therapeutics Offering

On average, firms in the Other Health Care sector, sell 68.60 % of the total offering size. Prevail Therapeutics sold 87.69 % of the offering. The financing is still open. Could this mean that the trust in Prevail Therapeutics is high? The average offering amount for companies in the Other Health Care industry is $1.16 million. The total amount raised is 4,813.80 % bigger than the average for companies in the Other Health Care sector. The minimum investment for this offering was set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Prevail Therapeutics Also

The Form D signed by ASA ABELIOVICH might help Prevail Therapeutics Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: